These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39063966)

  • 1. Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65).
    Benucci M; Bardelli M; Cazzato M; Bartoli F; Damiani A; Li Gobbi F; Bandinelli F; Panaccione A; Di Cato L; Niccoli L; Frediani B; Mosca M; Guiducci S; Cantini F
    J Pers Med; 2024 Jul; 14(7):. PubMed ID: 39063966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-
    Benucci M; Li Gobbi F; Damiani A; Russo E; Guiducci S; Manfredi M; Lari B; Grossi V; Infantino M
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542045
    [No Abstract]   [Full Text] [Related]  

  • 3. ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice.
    Benucci M; Bardelli M; Cazzato M; Laurino E; Bartoli F; Damiani A; Li Gobbi F; Panaccione A; Di Cato L; Niccoli L; Frediani B; Mosca M; Guiducci S; Cantini F
    J Pers Med; 2023 Aug; 13(9):. PubMed ID: 37763071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
    Combe B; Besuyen R; Gómez-Centeno A; Matsubara T; Sancho Jimenez JJ; Yin Z; Buch MH
    Rheumatol Ther; 2023 Feb; 10(1):35-51. PubMed ID: 36205910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis.
    Benucci M; Gobbi FL; Fusi P; Damiani A; Russo E; Guiducci S; Manfredi M; Grossi V; Infantino M; Amedei A
    Front Biosci (Landmark Ed); 2023 Aug; 28(8):176. PubMed ID: 37664943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis.
    Balsa A; Wassenberg S; Tanaka Y; Tournadre A; Orzechowski HD; Rajendran V; Lendl U; Stiers PJ; Watson C; Caporali R; Galloway J; Verschueren P
    Rheumatol Ther; 2023 Dec; 10(6):1555-1574. PubMed ID: 37747626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
    Castaño G; Mas R; Fernández L; Illnait J; Mesa M; Alvarez E; Lezcay M
    Drugs Aging; 2003; 20(2):153-63. PubMed ID: 12534315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
    Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
    Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
    Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis.
    Corrao S
    Intern Emerg Med; 2023 Nov; 18(8):2157-2161. PubMed ID: 37898967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
    Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
    Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience.
    La Barbera L; Rizzo C; Camarda F; Atzeni F; Miceli G; Molica Colella AB; Franchina V; Giardina A; Corrao S; Provenzano G; Bursi R; Foti R; Dal Bosco Y; Debilio C; Luppino F; Colaci M; Aprile ML; Bentivegna M; Cassarà E; Lo Gullo A; De Andres MI; Guggino G
    Clin Exp Rheumatol; 2024 May; 42(5):991-998. PubMed ID: 38197190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
    Charles-Schoeman C; DeMasi R; Valdez H; Soma K; Hwang LJ; Boy MG; Biswas P; McInnes IB
    Arthritis Rheumatol; 2019 Sep; 71(9):1450-1459. PubMed ID: 31385441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study.
    Pierini FS; Botta E; Soriano ER; Martin M; Boero L; Meroño T; Saez MS; Lozano Chiappe E; Cerda O; Citera G; Gandino I; Rosa J; Sorroche P; Kontush A; Brites F
    Rheumatol Ther; 2021 Jun; 8(2):803-815. PubMed ID: 33811316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A six-month, multicenter, open-label, noncomparative, prospective, observational study of the efficacy and tolerability of atorvastatin in the primary care setting(estudio del control de las hiperlipidemiasen atención primaria): the cheap study.
    Gómez-Gerique JA; Alvarez-Sala LA; Armada B; Fernández-Arias I; Martinez J; Hernández G;
    Curr Ther Res Clin Exp; 2003 Jun; 64(6):338-54. PubMed ID: 24944383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events.
    Elshazly MB; Nicholls SJ; Nissen SE; St John J; Martin SS; Jones SR; Quispe R; Stegman B; Kapadia SR; Tuzcu EM; Puri R
    Am J Cardiol; 2016 Sep; 118(5):647-55. PubMed ID: 27392507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.
    Liao KP; Liu J; Lu B; Solomon DH; Kim SC
    Arthritis Rheumatol; 2015 May; 67(8):2004-10. PubMed ID: 25917955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.